Naruhiko Ikoma1, Mariela Blum2, Jeannelyn S Estrella3, Prajnan Das4, Wayne L Hofstetter5, Keith F Fournier1, Paul Mansfield1, Jaffer A Ajani2, Brian D Badgwell6. 1. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, FCT17.6010, Houston, TX, 77030, USA. 2. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, FCT17.6010, Houston, TX, 77030, USA. bbadgwell@mdanderson.org.
Abstract
BACKGROUND: The American Joint Committee on Cancer (AJCC) recently released its 8th edition staging system, which created a separate staging system for gastric cancer patients who have undergone preoperative therapy (ypStage). The objective of this retrospective study was to apply the new ypStage to patients who have undergone preoperative therapy and potentially curative gastrectomy. METHODS: We collected data from a prospectively maintained institutional database of gastric cancer patients who underwent potentially curative gastrectomy after preoperative therapy (1995-2015). Kaplan-Meier survival estimations and log-rank tests were performed to compare survival. Univariable and multivariable analyses were performed to determine risk factors for overall survival. RESULTS: A total of 354 patients met our criteria. Most patients completed planned preoperative therapy (94%; 332/354) and received chemoradiation therapy (75%; 265/354). Although clinical stage (cStage) provided a poor discrimination of survival, postneoadjuvant pathological stage (ypStage) identified significant variation in survival (p < 0.001). Multivariable analysis showed the following factors were associated with survival after adjustment for ypStage: Asian race (HR 0.52; p = 0.028), linitis plastica (HR 1.66; p = 0.037), and R1 resection (HR 1.91; p = 0.016). Survival was not longer in ypT0N0 patients than in ypStage I patients (HR 1.29; p = 0.377). CONCLUSIONS: The AJCC 8th edition staging system for gastric cancer demonstrated reasonable survival prediction by ypStage, but not cStage, in patients who had undergone preoperative therapy. ypT0N0 patients, although not defined in the 8th edition, may be considered for inclusion in the ypStage I group.
BACKGROUND: The American Joint Committee on Cancer (AJCC) recently released its 8th edition staging system, which created a separate staging system for gastric cancerpatients who have undergone preoperative therapy (ypStage). The objective of this retrospective study was to apply the new ypStage to patients who have undergone preoperative therapy and potentially curative gastrectomy. METHODS: We collected data from a prospectively maintained institutional database of gastric cancerpatients who underwent potentially curative gastrectomy after preoperative therapy (1995-2015). Kaplan-Meier survival estimations and log-rank tests were performed to compare survival. Univariable and multivariable analyses were performed to determine risk factors for overall survival. RESULTS: A total of 354 patients met our criteria. Most patients completed planned preoperative therapy (94%; 332/354) and received chemoradiation therapy (75%; 265/354). Although clinical stage (cStage) provided a poor discrimination of survival, postneoadjuvant pathological stage (ypStage) identified significant variation in survival (p < 0.001). Multivariable analysis showed the following factors were associated with survival after adjustment for ypStage: Asian race (HR 0.52; p = 0.028), linitis plastica (HR 1.66; p = 0.037), and R1 resection (HR 1.91; p = 0.016). Survival was not longer in ypT0N0 patients than in ypStage I patients (HR 1.29; p = 0.377). CONCLUSIONS: The AJCC 8th edition staging system for gastric cancer demonstrated reasonable survival prediction by ypStage, but not cStage, in patients who had undergone preoperative therapy. ypT0N0 patients, although not defined in the 8th edition, may be considered for inclusion in the ypStage I group.
Authors: Min P Kim; Arlene M Correa; Jared Lee; David C Rice; Jack A Roth; Reza J Mehran; Garrett L Walsh; Jaffer A Ajani; Dipen M Maru; Joe Y Chang; Edith M Marom; Homer A Macapinlac; Jeff H Lee; Ara A Vaporciyan; Thomas Rice; Stephen G Swisher; Wayne L Hofstetter Journal: Ann Thorac Surg Date: 2010-09 Impact factor: 4.330
Authors: Cheguevara Afaneh; Adam Levy; Luke Selby; Geoffrey Ku; Laura Tang; Sam S Yoon; Daniel Coit; Vivian E Strong Journal: J Gastrointest Surg Date: 2015-09-24 Impact factor: 3.452
Authors: Naruhiko Ikoma; Mariela Blum; Yi-Ju Chiang; Jeannelyn S Estrella; Sinchita Roy-Chowdhuri; Keith Fournier; Paul Mansfield; Jaffer A Ajani; Brian D Badgwell Journal: Ann Surg Oncol Date: 2016-07-06 Impact factor: 5.344
Authors: Trevor Leong; B Mark Smithers; Michael Michael; Val Gebski; Alex Boussioutas; Danielle Miller; John Simes; John Zalcberg; Karin Haustermans; Florian Lordick; Christoph Schuhmacher; Carol Swallow; Gail Darling; Rebecca Wong Journal: BMC Cancer Date: 2015-07-21 Impact factor: 4.430
Authors: Juliana Silveira Lima de Castro; Adriane Graicer Pelosof; João Guilherme Guerra de Andrade-Cabral; Alvaro Moura Seraphim; Eloy Taglieri; Felipe Jose Fernandez Coimbra; Claudia Zitron Journal: Arq Bras Cir Dig Date: 2022-01-05
Authors: Casey J Allen; Alisa N Blumenthaler; Grace L Smith; Prajnan Das; Bruce D Minsky; Mariela Blum; Jaffer Ajani; Paul F Mansfield; Naruhiko Ikoma; Brian D Badgwell Journal: Ann Surg Oncol Date: 2020-07-21 Impact factor: 5.344
Authors: Casey J Allen; David T Pointer; Alisa N Blumenthaler; Rutika J Mehta; Sarah E Hoffe; Bruce D Minsky; Grace L Smith; Mariela Blum; Paul F Mansfield; Naruhiko Ikoma; Prajnan Das; Jaffer Ajani; Sean P Dineen; Jason B Fleming; Brian D Badgwell; Jose M Pimiento Journal: Ann Surg Date: 2021-10-01 Impact factor: 13.787
Authors: Ching-Wei D Tzeng; Hop S Tran Cao; Christina L Roland; Mediget Teshome; Brian K Bednarski; Naruhiko Ikoma; Paul H Graham; Emily Z Keung; Christopher P Scally; Matthew H G Katz; Jeffrey E Gershenwald; Jeffrey E Lee; Jean-Nicolas Vauthey Journal: Surg Oncol Date: 2020-04-28 Impact factor: 3.279
Authors: Casey J Allen; Alisa N Blumenthaler; Prajnan Das; Bruce D Minsky; Mariela Blum; Sinchita Roy-Chowdhuri; Jaffer A Ajani; Naruhiko Ikoma; Paul F Mansfield; Brian D Badgwell Journal: World J Surg Oncol Date: 2020-02-17 Impact factor: 2.754